Interestingly, we found the overall ERBB3 expression in thyroid cancers is significantly underexpressed in other cancer types with 3.51-folds (thyroid cancers versus other cancers = 5.21 ± 0.24 versus 7.02 ± 0.08 fluorescence intensity-log2, P = 0.01), indicating ligand binding to this “kinase-dead” ERBB3 receptor leads to dimerization with another kinase-competent family member which is not acquired in thyroid cancer development [18, 19]. Here, ERBB3 is linked to thyroid gland carcinoma.